QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials Blog QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials QSP modeling for Parkinson’s disease tackles optimized standard-of-care, placebo response, and missing biomarkers. See how…Certara2026 年 6 月 11 日
Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations Live Events 机制性 MIDD:凭借坚实的科学基础实现监管成功 2026 年 6 月 30 日 - 12:00 PM – 2:00 PMCertara2026 年 6 月 10 日
Model Smarter, Not Harder: Introducing Model Designer Webinar Model Smarter, Not Harder: Introducing Model Designer 2026 年 6 月 30 日, 10:00 – 11:00 AM ET | 2026 年 7 月 2 日, 10:00 – 11:00…Danielle Pillsbury2026 年 6 月 10 日
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies Poster Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.Certara2026 年 6 月 9 日
The Case for Simulating Pregnancy Press Coverage 支持模拟孕妇用药剂量的理由 孕妇通常被排除在药物临床试验之外,这使得临床医生缺乏用药剂量的指导。Discover how…Certara2026 年 6 月 9 日
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients Publication Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…Certara2026 年 6 月 4 日
Applying AI-Driven Biosimulation to Drug Discovery Video Applying AI-Driven Biosimulation to Drug Discovery Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…Certara2026 年 6 月 2 日
Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib Publication Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…Dorottya Gui-Bodnar2026 年 5 月 28 日
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators On-Demand Webinar The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…Certara2026 年 5 月 26 日
Certainty US 2026 recap: advancing model-informed drug development right from the start Blog Certainty US 2026 recap: advancing model-informed drug development right from the start This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…Certara2026 年 5 月 26 日